

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the applications identified in the attached Schedule A and attached statement under 37 CFR 3.73(b).

I hereby appoint:

☒ Practitioners associated with the Customer Number: 88984

OR

☐ Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

Name	Registration Number

Name	Registration Number

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:

☒ The address associated with Customer Number: 88984

OR

<input type="checkbox"/> Firm or Individual Name			
Address			
City	State	Zip	
Country			
Telephone	Fax		


Assignee Name and Address:

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, California 94404

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

Company Name	GILEAD SCIENCES, INC.		
Name	Daniel W. Collins		
Signature		Date	July 5, 2011
Title	Sr. Director, Intellectual Property	Telephone	(650) 574-3000

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

SCHEDULE A

F&L Ref.	Gilead Ref.	Application No.	Title	Filing Date	Applicant(s)
045710-1801	08-0265	12/569,643	Method of Multidetector Computer Tomography	9/29/2009	Belardinelli et al.
045710-1900	05-0220	11/701,699	Process for Preparing an A2A-Adenosine Receptor Agonist and Its Polymorphs	2/2/2007	Zablocki et al.
045710-1901	05-0220-CIP	11/750,295	Process for Preparing an A2A-Adenosine Receptor Agonist and Its Polymorphs	5/17/2007	Zablocki et al.
045710-1902	05-0220-CIP-CON	12/687,077	Process for Preparing an A2A-Adenosine Receptor Agonist and Its Polymorphs	1/13/2010	Zablocki et al.
045710-1904	05-0220-CON	12/765,623	Process for Preparing an A2A-Adenosine Receptor Agonist and Its Polymorphs	4/22/2010	Zablocki et al.
045710-1951	02-0479-C	10/629,368	Myocardial Perfusion Imaging Method	7/29/2003	Belardinelli
045710-1952	02-0479-E	10/766,403	Myocardial Perfusion Imaging Methods and Compositions	1/27/2004	Belardinelli et al.
045710-1953	02-0479-C-CON	12/695,096	Myocardial Perfusion Imaging Method	1/27/2010	Belardinelli
045710-1957	02-0479-E	12/749,328	Myocardial Perfusion Imaging Methods and Compositions	3/29/2010	Belardinelli et al.
045710-2000	09-0423-S3	11/588,834	N-Pyrazole A2A Receptor Agonists	10/27/2006	Zablocki et al.
045710-2001	99-0423-S4	12/637,311	N-Pyrazole A2A Receptor Agonists	12/14/2009	Zablocki et al.
045710-2002	99-0423	09/338,185	N-Pyrazole A2A Receptor Agonists	6/22/1999	Zablocki et al.
045710-2003	99-0423-S	10/018,446	2-(N-Pyrazolo)Adenosines with Application as Adenosine A2A Receptor Agonists	6/21/2000	Zablocki et al.
045710-2006	99-0423-S4	12/968,110	N-Pyrazole A2A Receptor Agonists	12/14/2010	Zablocki et al.
045710-2050	99-0424-T3	12/491,791	C-Pyrazole A2A Receptor Agonists	6/25/2009	Zablocki et al.
045710-2103	00-0078-D1	11/070,768	Myocardial Perfusion Imaging Method	3/2/2005	Belardinelli et al.
045710-2104	00-0078-DCON	12/435,176	Method of Identifying Partial Agonists of the A2A Receptor	5/4/2009	Belardinelli et al.

045710-2251	04-869-A	11/253,322	Use of A2A Adenosine Receptor Agonists	10/19/2005	Toufigh et al.
045710-2252	04-0869-CON	12/637,583	Use of A2A Adenosine Receptor Agonists	12/14/2009	Toufigh et al.
045710-2351	06-0454-A	11/766,964	Use of A2A Adenosine Receptor Agonists in the Treatment of Ischemia	6/22/2007	Belardinelli et al.
045710-2401	06-0222	11/848,743	Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods	8/31/2007	Lieu et al.
045710-2402	06-0230	11/864,437	Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease	9/28/2007	Lieu et al.
045710-2403	06-0222-US-CIP	12/163,099	Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods	6/27/2008	Lieu et al.
045710-2501	07-0237	11/969,047	Myocardial Perfusion Imaging	1/3/2008	Lieu et al.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: ZABLOCKI et al.
Application No.: 09/338,185 Filed: 6/22/1999
Patent No.: 6,403,567 Issue Date: 6/11/2002
Docket Number: 045710-2002
Entitled: N-PYRAZOLE A2A ADENOSINE RECEPTOR AGONISTS
GILEAD SCIENCES, INC. CORPORATION
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title, and interest
The extent (by percentage) of its ownership interest is %

in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:


1. From: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palte To: CV Therapeutics, Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 010187, Frame 0341, or for which a copy thereof is attached.
2. From: Apex Merger Sub, Inc. and CV Therapeutics, Inc. To: Gilead Palo Alto, Inc.
The Merger Document was recorded in the United States Patent and Trademark Office
for which a copy thereof is attached.
3. From: Gilead Palo Alto, Inc. To: Gilead Sciences, Inc.
The document was recorded in the United States Patent and Trademark Office at Reel 026424, Frame 0925
or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.


Signature

Daniel W. Collins

Printed or Typed Name

Sr. Director, Intellectual Property

Title

July 5, 2011
Date

(650) 574-3000

Telephone Number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.